Hydroxyurea reduces infections in children with sickle cell anemia in Uganda.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
03 Jan 2024
Historique:
accepted: 16 12 2023
received: 21 06 2023
revised: 11 12 2023
medline: 4 1 2024
pubmed: 4 1 2024
entrez: 3 1 2024
Statut: aheadofprint

Résumé

After starting hydroxyurea treatment, Ugandan children with sickle cell anemia had 60% less severe or invasive infections, including malaria, bacteremia, respiratory tract infections and gastroenteritis, than before starting hydroxyurea treatment (incidence rate ratio =0.40 [95% confidence interval], 0.29-0.54, P<0.001).

Identifiants

pubmed: 38169476
pii: 506920
doi: 10.1182/blood.2023021575
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American Society of Hematology.

Auteurs

Ruth Namazzi (R)

College of Health Sciences, Makerere University, Kampala, Uganda.

Caitlin Bond (C)

Indiana University School of Medicine, Indianapolis, Indiana, United States.

Andrea Conroy (A)

Indiana University School of Medicine.

Dibyadyuti Datta (D)

Indiana University School of Medicine, Indianapolis, Indiana, United States.

Abner Tagoola (A)

Jinja Regional Referral Hospital, Jinja, Uganda.

Michael J Goings (MJ)

Indiana University School of Medicine, Indianapolis, Indiana, United States.

Jeong Hoon Jang (JH)

Yonsei University, Seoul, Korea, Republic of.

Russell E Ware (RE)

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States.

Robert O Opoka (RO)

Global Health Uganda, Uganda.

Chandy C John (CC)

Indiana University School of Medicine, Indianapolis, Indiana, United States.

Classifications MeSH